Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

DAVID R HARDTEN

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1508851387
CMS profile
113878
Location
MINNEAPOLIS, MN

General Payments · PY2018–2024

$110,173.43

  • Reported across 61 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$19,853.99

12 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Royalty or License $16,000.00 1
Consulting Fee $3,162.50 3
Food and Beverage $691.49 8

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Alcon Laboratories Inc $16,149.46 2
GLAUKOS CORPORATION $1,945.52 5
Dompe Farmaceutici S.p.A. $1,312.50 1
Sight Sciences, Inc. $148.29 1
Dompe US, Inc. $138.60 1
Bausch & Lomb Americas Inc. $136.55 1
Johnson & Johnson Surgical Vision, Inc. $23.07 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $28,479.83 9
PY2019 $10,090.46 13
PY2020 $1,800.00 1
PY2021 $23,710.77 10
PY2022 $6,357.88 8
PY2023 $19,880.50 8
PY2024 $19,853.99 12

Payment records · PY2024 (12)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Alcon Vision LLC $16,000.00 06/13/2024 Royalty or License Undisputed 01/23/2026 1110524183 CMS
Alcon Vision LLC $149.46 10/18/2024 Food and Beverage Undisputed 01/23/2026 1110620469 CMS
Bausch & Lomb Americas Inc. $136.55 10/19/2024 Food and Beverage Undisputed 01/23/2026 1140331705 CMS
Dompe Farmaceutici S.p.A. $1,312.50 03/21/2024 Consulting Fee Undisputed 01/23/2026 1150029835 CMS
Dompe US, Inc. $138.60 04/05/2024 Food and Beverage Undisputed 01/23/2026 1151401364 CMS
Glaukos Corporation $13.05 01/26/2024 Food and Beverage Undisputed 01/23/2026 1151988594 CMS
Glaukos Corporation $20.75 04/05/2024 Food and Beverage Undisputed 01/23/2026 1151988596 CMS
Glaukos Corporation $650.00 06/26/2024 Consulting Fee Undisputed 01/23/2026 1151973633 CMS
Glaukos Corporation $61.72 09/25/2024 Food and Beverage Undisputed 01/23/2026 1151988598 CMS
Glaukos Corporation $1,200.00 10/30/2024 Consulting Fee Undisputed 01/23/2026 1151973631 CMS
Johnson & Johnson Surgical Vision, Inc. $23.07 02/21/2024 Food and Beverage Undisputed 01/23/2026 1077598410 CMS
Sight Sciences, Inc. $148.29 09/06/2024 Food and Beverage Undisputed 01/23/2026 1151918804 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.